Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning ...
Cancer
Dec 24, 2012 |
5 / 5 (1) |
0
|
BIM gene variation in East Asians found to explain resistance to cancer drugs
A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.
Cancer
Mar 18, 2012 |
not rated yet |
0
|
Drug targets hard-to-reach leukemia stem cells responsible for relapses
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms ...
Cancer
Jan 17, 2013 |
3.7 / 5 (3) |
0
|
Novel test identifies patients most likely to benefit from ALK inhibition therapy
Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients ...
Medical research
Dec 12, 2012 |
not rated yet |
0
|
Researchers identify possible new oncogene and future therapy target
A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance ...
Cancer
Sep 11, 2012 |
5 / 5 (1) |
0
|
Therapy targets leukemia stem cells
New research takes aim at stubborn cancer stem cells that are thought to be responsible for treatment resistance and relapse. The study, published by Cell Press in the February 14 issue of the journal Cancer Cell, provid ...
Cancer
Feb 13, 2012 |
4 / 5 (4) |
0
Leukemia drug reverses tamoxifen-resistance in breast cancer cells
Taking a leukemia chemotherapy drug may help breast cancer patients who don't respond to tamoxifen overcome resistance to the widely-used drug, new research from the Kimmel Cancer Center at Jefferson suggests. ...
Cancer
Aug 01, 2011 |
not rated yet |
0
|
New drug shows potential for treatment-resistant leukemia
A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.
Cancer
Apr 11, 2011 |
not rated yet |
0
Multi-tasking imatinib boosts radiotherapy for bladder tumours
Cancer drug imatinib (Glivec) could boost radiotherapy treatment to destroy bladder cancer that has spread to the bladder wall, reveals research published in Cancer Research.
Cancer
Mar 04, 2013 |
not rated yet |
0
Options increase for CML patients failed by existing drugs
The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved ...
Cancer
Dec 21, 2012 |
not rated yet |
0
Improved treatments for chronic myeloid leukaemia have dramatically increased survival
Survival for people diagnosed with Chronic Myeloid Leukaemia (CML) has risen by nearly half, with around 58 per cent of people surviving their disease for at least five years compared with only around 40 p ...
Cancer
Dec 12, 2012 |
not rated yet |
0
Drug combination acts against aggressive chronic lymphocytic leukemia
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of ...
Cancer
Dec 10, 2012 |
5 / 5 (2) |
0
Cabozantinib active in castration-resistant prostate cancer
(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. ...
Cancer
Dec 03, 2012 |
not rated yet |
0
Clinical trial delivers good results in leukemia patients
Huntsman Cancer Institute (HCI) researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard ...
Cancer
Nov 30, 2012 |
not rated yet |
0
A genetic variation common in East Asian populations has been linked to cancer drug resistance
Tyrosine kinase inhibitors (TKIs) kill cancerous cells by inducing programmed cell death. They are of enormous therapeutic benefit to patients with chronic myeloid leukemia (CML) and certain types of lung ...
Genetics
Aug 02, 2012 |
not rated yet |
0
